This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT)

This study has been withdrawn prior to enrollment.
(PI relocated)
University of Tennessee
Information provided by:
Methodist Healthcare Identifier:
First received: January 4, 2008
Last updated: September 12, 2016
Last verified: June 2009
The purpose of this study is to test the safety and efficacy of fondaparinux in patients with heparin-induced thrombocytopenia (HIT). The primary objective is to ensure that patients with HIT who are treated with fondaparinux experience a prompt and complete recovery of their platelet count, and the secondary objective is to determine if any new blood clots are formed while receiving the fondaparinux and up to one month after study enrollment. This information will be compared to a historical control.

Condition Intervention Phase
Heparin-Induced Thrombocytopenia Drug: fondaparinux Drug: argatroban or lepirudin Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia

Resource links provided by NLM:

Further study details as provided by Methodist Healthcare:

Primary Outcome Measures:
  • Platelet count recovery [ Time Frame: 5 days ]

Secondary Outcome Measures:
  • Recurrent thromboembolic complications [ Time Frame: 4 weeks ]

Enrollment: 0
Study Start Date: January 2008
Study Completion Date: July 2010
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
Drug: fondaparinux
fondaparinux subcutaneous injection once daily until INR stable in therapeutic range, at least five days: 5 mg if less than 50 kg, 7.5 mg if 50-100 kg, 10 mg if >100 kg
Other Name: Arixtra
Active Comparator: B
Direct thrombin inhibitor
Drug: argatroban or lepirudin
continuous infusion titrated into therapeutic range and for at least 5 days and until INR stable in therapeutic range
Other Name: Refludan


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female at least 18 years of age;
  • If female of childbearing potential, negative pregnancy test result;
  • Diagnosis of HIT confirmed by the following: Decreased platelet count by 50% or greater OR platelets < 100,000/mm3 during or within 2 weeks after heparin exposure and/or new thromboembolic complications during or within 2 weeks after heparin exposure;
  • Laboratory confirmation (either heparin PF4 antibody or serotonin release assay positive).

Exclusion Criteria:

  • Estimated creatinine clearance less than 30 ml/min (either measured or by using Cockcroft Gault equation);
  • Pregnancy or lactating;
  • Blood dyscrasia other than HIT;
  • History of thrombocytopenia associated with fondaparinux;
  • Recent (within 6 weeks) or planned surgery of CNS, eye or traumatic surgery resulting in large open surfaces or other procedures with high bleeding risk or if lumbar puncture is planned;
  • Active bleeding of GI tract, GU tract, CNS or respiratory tract;
  • Malignant hypertension, pericarditis, pericardial effusion, endocarditis or eclampsia;
  • Inadequate laboratory facilities, inadequate support system at home, alcoholism, drug abuse, psychosis or dementia;
  • Hypersensitivity or contraindication to warfarin or fondaparinux.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00603824

Sponsors and Collaborators
Methodist Healthcare
University of Tennessee
Principal Investigator: Bob L Lobo, Pharm.D. Methodist University Hospital
Principal Investigator: Sohail Minhas, MD University of Tennessee
  More Information

Responsible Party: Bob Lobo, Program Director, Clinical Pharmacy, Vanderbilt University Identifier: NCT00603824     History of Changes
Other Study ID Numbers: MHIRB # 2007-058
Study First Received: January 4, 2008
Last Updated: September 12, 2016

Keywords provided by Methodist Healthcare:
heparin-Induced thrombocytopenia

Additional relevant MeSH terms:
Blood Platelet Disorders
Hematologic Diseases
Calcium heparin
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Platelet Aggregation Inhibitors processed this record on August 18, 2017